C4 Therapeutics, Inc.
CCCCNASDAQHealthcare● Active
$3.59
$-0.26(-6.75%)
Market Cap$297349605
P/E Ratio—
52W High$4.598
52W Low$1.36
C4 Therapeutics, Inc. (CCCC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CCCC · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.20
Est. -$0.25 · +20.2%
Revenue
$0.01B
Est. $0.00B · +40.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 5-Quarter EPS Beat Streak
CCCC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.23 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.25 | -$0.20 | +20.2% | $0.01B | $0.00B | +40.4% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.31 | -$0.18 | +41.9% | $0.01B | $0.01B | +104.2% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.47 | -$0.44 | +6.4% | $0.01B | $0.00B | +150.7% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.38 | -$0.37 | +2.6% | $0.01B | $0.01B | -5.0% |
| ▲ Q2 FY2025 | May 7, 2025 | -$0.48 | -$0.37 | +22.9% | $0.01B | $0.00B | +104.5% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -$0.44 | -$0.49 | -11.4% | $0.01B | $0.00B | +55.3% |
| ▲ Q4 FY2024 | Oct 31, 2024 | -$0.40 | -$0.35 | +12.5% | $0.02B | $0.00B | +360.9% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.20
EPS Est.
-$0.25
EPS Surpr.
+20.2%
Revenue
$0.01B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.31
EPS Surpr.
+41.9%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.44
EPS Est.
-$0.47
EPS Surpr.
+6.4%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.37
EPS Est.
-$0.38
EPS Surpr.
+2.6%
Revenue
$0.01B
Q2 FY2025
May 7, 2025Beat
EPS Actual
-$0.37
EPS Est.
-$0.48
EPS Surpr.
+22.9%
Revenue
$0.01B
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
-$0.49
EPS Est.
-$0.44
EPS Surpr.
-11.4%
Revenue
$0.01B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
-$0.35
EPS Est.
-$0.40
EPS Surpr.
+12.5%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q3 FY2027 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q2 FY2027 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q1 FY2027 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q4 FY2026 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q3 FY2026 | $-0.25 | $-0.25 | $-0.25 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +20.2% | $3.17 | $3.17 | +0.00% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +41.9% | $2.77 | $2.78 | +0.36% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +6.4% | $2.37 | $2.38 | +0.42% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +2.6% | $1.96 | $2.58 | +31.63% |
| ▲ Q2 FY2025 | May 7, 2025 | +22.9% | $1.41 | $1.50 | +6.38% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -11.4% | $2.65 | $2.60 | -1.89% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +12.5% | $5.53 | $5.33 | -3.62% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +29.7% | $6.70 | $6.68 | -0.30% |
Q2 FY2026+0.00%
Report Date
May 12, 2026
EPS Beat/Miss
+20.2%
Price Before
$3.17
Price After
$3.17
Q1 FY2026+0.36%
Report Date
Feb 26, 2026
EPS Beat/Miss
+41.9%
Price Before
$2.77
Price After
$2.78
Q4 FY2025+0.42%
Report Date
Nov 6, 2025
EPS Beat/Miss
+6.4%
Price Before
$2.37
Price After
$2.38
Q3 FY2025+31.63%
Report Date
Aug 7, 2025
EPS Beat/Miss
+2.6%
Price Before
$1.96
Price After
$2.58
Q2 FY2025+6.38%
Report Date
May 7, 2025
EPS Beat/Miss
+22.9%
Price Before
$1.41
Price After
$1.50
Q1 FY2025-1.89%
Report Date
Feb 27, 2025
EPS Beat/Miss
-11.4%
Price Before
$2.65
Price After
$2.60
Q4 FY2024-3.62%
Report Date
Oct 31, 2024
EPS Beat/Miss
+12.5%
Price Before
$5.53
Price After
$5.33
Q3 FY2024-0.30%
Report Date
Aug 1, 2024
EPS Beat/Miss
+29.7%
Price Before
$6.70
Price After
$6.68
Avg Beat Reaction+4.98%
Avg Miss Reaction-1.89%
Beat Rate7 / 8 quarters
Largest Move+31.63% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CCCC ends December
C4 Therapeutics, Inc. (CCCC) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.20 — beating the analyst consensus of $-0.25 by +20.2%. CCCC has beaten EPS estimates for 5 consecutive quarters. The next CCCC earnings date is expected around September 1, 2026.
Each quarter, investors track CCCC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CCCC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CCCC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CCCC earnings · 5 questionsC4 Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CCCC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CCCC historically reports after market close (AMC).
CCCC earnings datewhen is CCCC earningsCCCC next earnings datewhen does CCCC report earningsCCCC earnings calendar
▸ Source: FMP · C4 Therapeutics, Inc. SEC filings · US GAAP · C4 Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026